Phosphonic Acids (Phosphonates)

Inorganic or organic derivatives of phosphonic acid with the general formula ROP(OH)2 or RP(=O)(OH)2. The tautomeric form of this compound (P(OH)3) is PHOSPHOROUS ACIDS. Nucleoside phosphonates have a phosphate-carbon bond that is more resistant to enzymatic cleavage than the normal phosphate-oxygen bond.
Also Known As:
Phosphonates; Phosphonic Acid Esters; Acid Esters, Phosphonic; Acids, Phosphonic; Esters, Phosphonic Acid
Networked: 103 relevant articles (10 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Holý, Antonín: 10 articles (01/2012 - 08/2003)
2. De Clercq, Erik: 8 articles (07/2011 - 10/2003)
3. Votruba, Ivan: 6 articles (09/2010 - 11/2003)
4. Hostetler, Karl Y: 6 articles (01/2010 - 02/2007)
5. Beadle, James R: 5 articles (01/2010 - 02/2007)
6. Pohl, Radek: 4 articles (04/2015 - 01/2007)
7. Guddat, Luke W: 3 articles (04/2015 - 01/2011)
8. Keough, Dianne T: 3 articles (04/2015 - 01/2011)
9. Dračínský, Martin: 2 articles (08/2015 - 01/2012)
10. Česnek, Michal: 2 articles (08/2015 - 01/2012)

Related Diseases

1. Infection
2. Retroviridae Infections (Infection, Retrovirus)
11/01/2005 - "Almost 20 years after the broad antiviral activity spectrum of the first acyclic nucleoside phosphonates was described, several of these compounds have become important therapies for DNA virus and retrovirus infections. "
06/01/2003 - "Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections."
01/01/1998 - "Acyclic nucleoside phosphonates: a new dimension to the chemotherapy of DNA virus and retrovirus infections."
10/01/2003 - "Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections."
10/01/2003 - "The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. "
3. HIV Infections (HIV Infection)
07/01/2013 - "AZT 5'-Phosphonates: Achievements and Trends in the Treatment and Prevention of HIV Infection."
12/01/2008 - "To determine if this strategy would be effective for certain phosphonomethoxyethyl nucleoside phosphonates which are also active against HIV infections, the hexadecyloxypropyl (HDP) esters of 1-(phosphonomethoxyethyl)-cytosine, 1-(phosphonomethoxyethyl)-5-bromo-cytosine (PME-5BrC), 1-(phosphonomethoxyethyl)-5-fluoro-cytosine, 9-(phosphonomethoxyethyl)-2,6-diaminopurine (PME-DAP), and 9-(phosphonomethoxyethyl)-2-amino-6-cyclopropylaminopurine (PME-cPrDAP) were evaluated for activity against herpesvirus replication. "
12/01/2001 - "Development of a novel group of antiviral agents, acyclic nucleoside phosphonates, has provided a new perspective for treating human immunodeficiency virus (HIV) infection. "
01/01/2007 - "In present experiments we analyzed effects of acyclic nucleoside phosphonates on gene expression of other members of the beta family of chemokines, monocyte chemotactic proteins (MCPs), which have also been implicated in the control of HIV infection. "
07/15/2011 - "This era has now grown to many more acyclic (and cyclic) nucleoside phosphonates (such as the "open ring" DAPy and Fd4A phosphonates) and alkoxyalkyl and phosphonoamidate prodrugs thereof, as well as new clinical applications, including new drug combination regimens for the treatment of AIDS, the chemoprophylaxis of HIV infections, and the anticancer potential against some malignant disorders."
4. Papilloma (Papillomatosis)
11/01/2005 - "Here, we review the discovery and development of acyclic nucleoside phosphonates, focusing on cidofovir and its potential in the treatment of various herpes-, papilloma-, polyoma-, adeno- and pox-virus infections, adefovir for the treatment of hepatitis B and tenofovir for the treatment of AIDS and the prevention of HIV infections."
04/01/2007 - "Nature 1986;323:464-7], the acyclic nucleoside phosphonates have acquired a prominent therapeutic position: (i) cidofovir in the treatment of papilloma-, herpes-, adeno- and poxvirus infections, (ii) adefovir in the treatment of chronic hepatitis B virus (HBV) infections, and (iii) tenofovir in the treatment of human immunodeficiency virus (HIV) infections (AIDS). "
06/01/2003 - "The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and PMPA: tenofovir, Viread] have proven to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections, for example, cidofovir against herpesvirus [herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus type 6, 7 and 8), polyoma-, papilloma-, adeno- and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus and orf) infections; adefovir against herpesvirus, hepadnavirus [human hepatitis B virus] and retrovirus [HIV type-1 and 2, simian immunodeficiency virus and feline immunodeficiency virus] infections; and tenofovir against both hepadna- and retrovirus infections. "
07/01/2010 - "The stories told in part D focus on: (i) the cyclotriazadisulfonamide compounds; (ii) the {5-[(4-bromophenylmethyl]-2-phenyl-5H-imidazo[4,5-c]pyridine} compounds; (iii) (1H,3H-thiazolo[3,4-a]benzimidazole) derivatives; (iv) T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) and (v) its structurally closely related analogue pyrazine 2-carboxamide (pyrazinamide); (vi) new strategies for the treatment of hemorrhagic fever virus infections, including, as the most imminent, (vii) dengue fever, (viii) the veterinary use of acyclic nucleoside phosphonates; (ix) the potential (off-label) use of cidofovir in the treatment of papillomatosis, particularly RRP (recurrent respiratory papillomatosis); and (x) finally, the prophylactic use of tenofovir to prevent HIV infections."
5. Contagious Ecthyma (Orf)

Related Drugs and Biologics

1. adefovir
2. cidofovir (Vistide)
3. tenofovir
4. pinacolyl methylphosphonic acid
5. Antiviral Agents (Antivirals)
6. adefovir dipivoxil (Hepsera)
7. tenofovir disoproxil (Viread)
8. Esters
9. 9-((2-phosphonylmethoxy)ethyl)guanine
10. 9- (2- phosphonylmethoxyethyl)- 2,6- diaminopurine

Related Therapies and Procedures

1. Chemoprevention
2. Drug Therapy (Chemotherapy)
3. Microspheres (Microsphere)
4. Off-Label Use
5. Hematopoietic Stem Cell Mobilization